C. BiotF. NostenL. FraisseD. Ter-MinassianJ. KhalifeD. DiveUniversity of LilleShoklo Malaria Research UnitMahidol UniversityNuffield Department of Clinical MedicineSanofi S.A.Centre d'Infection et d'Immunite de Lille2018-05-032018-05-032011-01-01Parasite. Vol.18, No.3 (2011), 207-214177610421252607X2-s2.0-84855268494https://repository.li.mahidol.ac.th/handle/20.500.14594/11390Ferroquine (FQ, SSR97193) is currently the most advanced organometallic drug candidate and about to complete phase II clinical trials as a treatment for uncomplicated malaria. This ferrocene-containing compound is active against both chloroquine-susceptible and chloroquine-resistant Plasmodium falciparum and P. vivax strains and/or isolates. This article focuses on the discovery of FQ, its antimalarial activity, the hypothesis of its mode of action, the current absence of resistance in vitro and recent clinical trials.Mahidol UniversityAgricultural and Biological SciencesImmunology and MicrobiologyReviewSCOPUS10.1051/parasite/2011183207